AU7629594A - Imidazoles for treating cytokine mediated disease - Google Patents

Imidazoles for treating cytokine mediated disease

Info

Publication number
AU7629594A
AU7629594A AU76295/94A AU7629594A AU7629594A AU 7629594 A AU7629594 A AU 7629594A AU 76295/94 A AU76295/94 A AU 76295/94A AU 7629594 A AU7629594 A AU 7629594A AU 7629594 A AU7629594 A AU 7629594A
Authority
AU
Australia
Prior art keywords
imidazoles
mediated disease
cytokine mediated
treating cytokine
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76295/94A
Inventor
Jerry Leroy Adams
Timothy Francis Gallagher
John C. Lee
John Richard White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU7629594A publication Critical patent/AU7629594A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU76295/94A 1993-07-21 1994-07-21 Imidazoles for treating cytokine mediated disease Abandoned AU7629594A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9523493A 1993-07-21 1993-07-21
US095234 1993-07-21
PCT/US1994/008297 WO1995003297A1 (en) 1993-07-21 1994-07-21 Imidazoles for treating cytokine mediated disease

Publications (1)

Publication Number Publication Date
AU7629594A true AU7629594A (en) 1995-02-20

Family

ID=22250839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76295/94A Abandoned AU7629594A (en) 1993-07-21 1994-07-21 Imidazoles for treating cytokine mediated disease

Country Status (3)

Country Link
AU (1) AU7629594A (en)
WO (1) WO1995003297A1 (en)
ZA (1) ZA945363B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
EP0607775B1 (en) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Use of leflunomid for the inhibition of interleukin 1 beta
ATE174217T1 (en) * 1993-01-08 1998-12-15 Hoechst Ag USE OF LEFLUNOMIDE TO INHIBIT INTERLEUKIN 1 ALPHA
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
DE69531956T2 (en) * 1994-12-13 2004-07-29 F. Hoffmann-La Roche Ag IMIDAZOLE DERIVATIVES WITH PROTEIN KINASE, IN PARTICULAR EGF-R TYROSINKINASE, INHIBITING EFFECT
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
SK282496B6 (en) * 1995-10-06 2002-02-05 Merck & Co., Inc. Imidazole derivatives, pharmaceutical preparation containing them and their use
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
ATE294174T1 (en) * 1996-06-10 2005-05-15 Merck & Co Inc SUBSTITUTED IMIDAZOLES WITH CYTOKININ INHIBITORY EFFECT
EP0812829A1 (en) * 1996-06-14 1997-12-17 Ontogen Corporation Substituted imidazoles as modulators of multi-drug resistance
CA2271963A1 (en) * 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
AU730295B2 (en) * 1996-11-20 2001-03-01 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US5880139A (en) * 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
PT988301E (en) 1997-06-12 2006-10-31 Aventis Pharma Ltd CICID ACIDS OF IMIDAZOLYL
US20020156104A1 (en) 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
JP2002515915A (en) * 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 2-Substituted imidazoles useful in treating inflammatory diseases
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001518507A (en) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション New cycloalkenyl substituted compounds
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
WO2000002561A1 (en) * 1998-07-13 2000-01-20 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
JP2003525201A (en) 1998-08-20 2003-08-26 スミスクライン・ビーチャム・コーポレイション New substituted triazole compounds
EP1126852B1 (en) 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
ES2249309T3 (en) 1999-11-23 2006-04-01 Smithkline Beecham Corp COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
CO5271680A1 (en) * 2000-02-21 2003-04-30 Smithkline Beecham Corp COMPOUNDS
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03002449A (en) * 2000-09-21 2003-06-19 Smithkline Beecham Plc Imidazole derivatives as raf kinase inhibitors.
DE10107683A1 (en) 2001-02-19 2002-08-29 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituted imidazole derivatives and their use in pharmacy
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
ES2497116T3 (en) 2002-08-19 2014-09-22 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as antimicrobial agents
EP2251343A1 (en) 2003-05-15 2010-11-17 Arqule, Inc. Imidazothiazoles as p38-kinase-inhibitors
AU2004275888B2 (en) 2003-10-02 2008-09-18 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
JP2008517064A (en) 2004-10-19 2008-05-22 アークル インコーポレイテッド Synthesis of imidazooxazole and imidazothiazole inhibitors of P38 MAP kinase
EP1915374B1 (en) 2005-05-25 2014-04-02 Lorus Therapeutics Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
KR20140074259A (en) * 2011-05-17 2014-06-17 조인트 스톡 컴퍼니 “파르마신세즈” Compounds for adhesion treatment and prevention, compound-related pharmaceutical compositions and methods for the prevention and treatment of adhesions
CN105308050A (en) 2013-03-20 2016-02-03 艾普托斯生物科学公司 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer
WO2015051302A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions and methods for treating cancers
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
RU2624228C1 (en) * 2016-01-20 2017-07-03 Акционерное Общество "Фармасинтез" Compounds for adhesion treatment or prevention, pharmaceutical compositions based thereon and method for adhesion process prevention and treatment
EP3429603B1 (en) 2016-03-15 2021-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
TW201936190A (en) 2017-10-30 2019-09-16 加拿大商艾普托斯生物科學公司 Aryl imidazoles for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles

Also Published As

Publication number Publication date
ZA945363B (en) 1995-03-14
WO1995003297A1 (en) 1995-02-02

Similar Documents

Publication Publication Date Title
AU7629594A (en) Imidazoles for treating cytokine mediated disease
EP0727998A4 (en) Oxazoles for treating cytokine mediated diseases
AU4944093A (en) Osteosynthesis aid
AU5975694A (en) Electrotherapeutic apparatus
AU4530993A (en) Leachate treatment system
AU5969490A (en) Steerable intramedullary fracture reduction device
AU3802493A (en) Surgical endoclip
AU5457096A (en) Gene-transfer-mediated angiogenesis therapy
AU3986195A (en) Osteosynthesis apparatus
AU1072695A (en) Dressing
AU4139196A (en) Method and composition for antiviral therapy
AU1090795A (en) Method for preventing tissue injury from hypoxia
AU1248395A (en) Bandages
AU3351693A (en) Anatomical air-mattress
AU7363691A (en) Methods for treating interleukin-1 mediated diseases
AU1480497A (en) Cancer treatment
AU3679693A (en) Benzimidazoles
AU4584893A (en) Magnetotherapy apparatus
AU7166896A (en) Cancer treatment
AU4511493A (en) Microwave treatment apparatus
AU4840893A (en) Surgical apparatus
AU5340594A (en) Skin treatment
AU3170293A (en) Therapeutic nucleosides
AU4859193A (en) Process for polymerizing alpha-olefin
AU2547895A (en) Therapeutic phenoxyalkylheterocycles